JACC. Heart failure最新文献

{"title":"Immune Checkpoint Inhibitors Myocarditis","authors":"Andriana P. Nikolova MD, PhD , Bonnie Ky MD, MSCE","doi":"10.1016/j.jchf.2024.07.011","DOIUrl":"10.1016/j.jchf.2024.07.011","url":null,"abstract":"","PeriodicalId":14687,"journal":{"name":"JACC. Heart failure","volume":"12 10","pages":"Pages 1794-1796"},"PeriodicalIF":10.3,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142107493","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Controversies and Conundrums in Cardiac Cachexia","authors":"","doi":"10.1016/j.jchf.2024.03.003","DOIUrl":"10.1016/j.jchf.2024.03.003","url":null,"abstract":"<div><div>Cardiac cachexia<span><span> is characterized by unintentional catabolic weight loss, decreased appetite, and inflammation and is common in patients with stage D (advanced) </span>heart failure with reduced ejection fraction<span> (HFrEF). Cardiac cachexia and related muscle-wasting syndromes are markers of, and a consequence of, the heart failure (HF) syndrome. Although many potential modalities for identifying cardiac cachexia exist, the optimal definition, diagnostic tools, and treatment options for cardiac cachexia remain unclear. Furthermore, it remains unclear whether attempts to reverse muscle wasting<span><span><span> prior to advanced HF surgeries, such as left ventricular assist devices and </span>heart transplantation<span>, can improve outcomes. It is important that HF clinicians and dietitians are aware of the pathophysiology and mechanisms of muscle-wasting syndromes in patients with HF, to aid in the recognition and </span></span>risk stratification<span> of advanced HFrEF. Although the opportunities and rationale for attempting to address cardiac cachexia prior to advanced HF surgeries are uncertain, recent publications suggest that control of the neurohumoral syndrome of advanced HF may be important to permit the recovery of skeletal muscle mass.</span></span></span></span></div></div>","PeriodicalId":14687,"journal":{"name":"JACC. Heart failure","volume":"12 10","pages":"Pages 1645-1660"},"PeriodicalIF":10.3,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140898327","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association Between Cardiovascular Health and Lifetime Risk of Heart Failure","authors":"Neela D. Thangada MD ,&nbsp;Arjun Sinha MD ,&nbsp;Hongyan Ning MD, MS ,&nbsp;Amanda Paluch PhD ,&nbsp;Victor W. Zhong PhD ,&nbsp;Norrina B. Allen PhD, MPH ,&nbsp;Mercedes R. Carnethon PhD, MS ,&nbsp;John T. Wilkins MD, MSCI ,&nbsp;Donald M. Lloyd-Jones MD, ScM ,&nbsp;Sadiya S. Khan MD, MS","doi":"10.1016/j.jchf.2024.06.015","DOIUrl":"10.1016/j.jchf.2024.06.015","url":null,"abstract":"","PeriodicalId":14687,"journal":{"name":"JACC. Heart failure","volume":"12 10","pages":"Pages 1788-1790"},"PeriodicalIF":10.3,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141901786","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Contemporary Patterns of Medicare and Medicaid Utilization and Associated Spending on Tafamidis in Cardiac Amyloidosis","authors":"Kannu Bansal MD ,&nbsp;Vidit Majmundar MD ,&nbsp;Grant M. Young BS ,&nbsp;Ralph J. Riello III PharmD ,&nbsp;Kamil F. Faridi MD, MSc ,&nbsp;Tariq Ahmad MD, MPH ,&nbsp;Nihar R. Desai MD, MPH","doi":"10.1016/j.jchf.2024.07.002","DOIUrl":"10.1016/j.jchf.2024.07.002","url":null,"abstract":"","PeriodicalId":14687,"journal":{"name":"JACC. Heart failure","volume":"12 10","pages":"Pages 1791-1793"},"PeriodicalIF":10.3,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141901787","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"National Trends in Heart Failure Hospitalizations and Readmissions From 2010 to 2021.","authors":"Manyoo A Agarwal, Gregg C Fonarow, Boback Ziaeian","doi":"10.1016/j.jchf.2024.08.016","DOIUrl":"https://doi.org/10.1016/j.jchf.2024.08.016","url":null,"abstract":"","PeriodicalId":14687,"journal":{"name":"JACC. Heart failure","volume":" ","pages":""},"PeriodicalIF":10.3,"publicationDate":"2024-09-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142371870","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Coronary Revascularization in Ischemic Systolic Heart Failure","authors":"Yousif Ahmad PhD","doi":"10.1016/j.jchf.2024.06.003","DOIUrl":"10.1016/j.jchf.2024.06.003","url":null,"abstract":"","PeriodicalId":14687,"journal":{"name":"JACC. Heart failure","volume":"12 9","pages":"Pages 1563-1565"},"PeriodicalIF":10.3,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141633532","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Incidence and Prediction of Anoxic Brain Injury in Concomitant Cardiac Arrest and Cardiogenic Shock","authors":"","doi":"10.1016/j.jchf.2024.05.009","DOIUrl":"10.1016/j.jchf.2024.05.009","url":null,"abstract":"","PeriodicalId":14687,"journal":{"name":"JACC. Heart failure","volume":"12 9","pages":"Pages 1639-1642"},"PeriodicalIF":10.3,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141431897","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Continuum of Preshock to Classic Cardiogenic Shock in the Critical Care Cardiology Trials Network Registry","authors":"Siddharth M. Patel MD, MPH ,&nbsp;David D. Berg MD, MPH ,&nbsp;Erin A. Bohula MD, DPhil ,&nbsp;Vivian M. Baird-Zars MPH ,&nbsp;Jeong-Gun Park PhD ,&nbsp;Christopher F. Barnett MD, MPH ,&nbsp;Lori B. Daniels MD, MAS ,&nbsp;Christopher B. Fordyce MD, MHS, MSc ,&nbsp;Shahab Ghafghazi MD ,&nbsp;Michael J. Goldfarb MD, MSc ,&nbsp;Kari Gorder MD ,&nbsp;Younghoon Kwon MD ,&nbsp;Evan Leibner MD, PhD ,&nbsp;Venu Menon MD ,&nbsp;Brian J. Potter MD, MSc ,&nbsp;Rajnish Prasad MD ,&nbsp;Michael A. Solomon MD, MBA ,&nbsp;Jeffrey J. Teuteberg MD ,&nbsp;Andrea D. Thompson MD, PhD ,&nbsp;Sammy Zakaria MD, MPH ,&nbsp;David A. Morrow MD, MPH","doi":"10.1016/j.jchf.2024.06.009","DOIUrl":"10.1016/j.jchf.2024.06.009","url":null,"abstract":"<div><h3>Background</h3><p>The prognostic implications of phenotypes along the preshock to cardiogenic shock (CS) continuum remain uncertain.</p></div><div><h3>Objectives</h3><p>This study sought to better characterize pre- or early shock and normotensive CS phenotypes and examine outcomes compared to those with conventional CS.</p></div><div><h3>Methods</h3><p>The CCCTN (Critical Care Cardiology Trials Network) is a registry of contemporary cardiac intensive care units. Consecutive admissions (N = 28,703 across 47 sites) meeting specific criteria based on hemodynamic variables, perfusion parameters, and investigator-reported CS were classified into 1 of 4 groups or none: isolated low cardiac output (CO), heart failure with isolated hypotension, normotensive CS, or SCAI (Society of Cardiovascular Angiography and Intervention) stage C CS. Outcomes of interest were in-hospital mortality and incidence of subsequent hypoperfusion among pre- and early shock states.</p></div><div><h3>Results</h3><p>A total of 2,498 admissions were assigned to the 4 groups with the following distribution: 4.8% isolated low CO, 4.4% isolated hypotension, 12.1% normotensive CS, and 78.7% SCAI stage C CS. Overall in-hospital mortality was 21.3% (95% CI: 19.7%-23.0%), with a gradient across phenotypes (isolated low CO 3.6% [95% CI: 1.0%-9.0%]; isolated hypotension 11.0% [95% CI: 6.9%-16.6%]; normotensive CS 17.0% [95% CI 13.0%-21.8%]; SCAI stage C CS 24.0% [95% CI: 22.1%-26.0%]; global <em>P &lt;</em> 0.001). Among those with an isolated low CO and isolated hypotension on admission, 47 (42.3%) and 56 (30.9%) subsequently developed hypoperfusion.</p></div><div><h3>Conclusions</h3><p>In a large contemporary registry of cardiac critical illness, there exists a gradient of mortality for phenotypes along the preshock to CS continuum with risk for subsequent worsening of preshock states. These data may inform refinement of CS definitions and severity staging.</p></div>","PeriodicalId":14687,"journal":{"name":"JACC. Heart failure","volume":"12 9","pages":"Pages 1625-1635"},"PeriodicalIF":10.3,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141874822","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effect of PCI on Health Status in Ischemic Left Ventricular Dysfunction","authors":"","doi":"10.1016/j.jchf.2024.03.010","DOIUrl":"10.1016/j.jchf.2024.03.010","url":null,"abstract":"<div><h3>Background</h3><p>In the REVIVED-BCIS2 (Revascularization for Ischemic Ventricular Dysfunction) trial, percutaneous coronary intervention (PCI) did not reduce the incidence of death or hospitalization for heart failure (HHF).</p></div><div><h3>Objectives</h3><p>This prespecified secondary analysis investigated the effect of PCI on health status measured with the Kansas City Cardiomyopathy Questionnaire (KCCQ) combined with the primary outcome in a win ratio.</p></div><div><h3>Methods</h3><p>Participants with severe ischemic left ventricular dysfunction were randomized to either PCI in addition to optimal medical therapy (OMT) (PCI) or OMT alone (OMT). The primary outcome was a hierarchical composite of all-cause death, HHF, and KCCQ–Overall Summary Score (OSS) at 24 months analyzed using the unmatched win ratio. The key secondary endpoint was a KCCQ-OSS responder analysis.</p></div><div><h3>Results</h3><p>A total of 347 participants were randomized to PCI and 353 to OMT. Median age was 70.0 years (Q1-Q3: 63.3-76.1 years). Mean left ventricular ejection fraction was 27.0 ± 6.7%. PCI did not improve the primary endpoint (win ratio for PCI vs OMT: 1.05; 95% CI: 0.88-1.26; <em>P =</em> 0.58). PCI resulted in more KCCQ-OSS responders than OMT at 6 months (54.1% vs 40.7%; OR: 1.96; 95% CI: 1.41-2.71; <em>P &lt;</em> 0.001) and fewer deteriorators (25.2% vs 31.4%; OR: 0.69; 95% CI: 0.47-1.00; <em>P =</em> 0.048). PCI did not impact KCCQ-OSS responders or deteriorators at 12 or 24 months.</p></div><div><h3>Conclusions</h3><p>PCI did not improve the hierarchical composite of death, HHF, and health status at 2 years. PCI improved KCCQ-OSS at 6 months, but this benefit was not sustained to 1- or 2-year follow-up. (Revacularization for Ischemic Ventricular Dysfunction [REVIVED-BCIS2]; <span><span>NCT01920048</span><svg><path></path></svg></span>)</p></div>","PeriodicalId":14687,"journal":{"name":"JACC. Heart failure","volume":"12 9","pages":"Pages 1553-1562"},"PeriodicalIF":10.3,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2213177924002646/pdfft?md5=599992f76d6c9bef61a09ab764c3cd1e&pid=1-s2.0-S2213177924002646-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140604242","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Obesity and Weight Loss Strategies for Patients With Heart Failure","authors":"Amanda R. Vest MBBS, MPH ,&nbsp;Philip R. Schauer MD ,&nbsp;Jo E. Rodgers PharmD ,&nbsp;Emily Sanderson BA, MS ,&nbsp;Courtney L. LaChute MD ,&nbsp;Jessica Seltz MS, RD ,&nbsp;Carl J. Lavie MD ,&nbsp;Stacy A. Mandras MD ,&nbsp;W.H. Wilson Tang MD ,&nbsp;Adrian daSilva-deAbreu MD, MSc","doi":"10.1016/j.jchf.2024.06.006","DOIUrl":"10.1016/j.jchf.2024.06.006","url":null,"abstract":"<div><p>Obesity is a common comorbidity among patients with heart failure with reduced ejection fraction (HFrEF) or heart failure with preserved ejection fraction (HFpEF), with the strongest pathophysiologic link of obesity being seen for HFpEF. Lifestyle measures are the cornerstone of weight loss management, but sustainability is a challenge, and there are limited efficacy data in the heart failure (HF) population. Bariatric surgery has moderate efficacy and safety data for patients with preoperative HF or left ventricular dysfunction and has been associated with reductions in HF hospitalizations and medium-term mortality. Antiobesity medications historically carried concerns for cardiovascular adverse effects, but the safety and weight loss efficacy seen in general population trials of glucagon-like peptide 1 (GLP-1) and gastric inhibitory polypeptide/GLP-1 agonists are highly encouraging. Although there are safety concerns regarding GLP-1 agonists in advanced HFrEF, trials of the GLP-1 agonist semaglutide for treatment of obesity have confirmed safety and efficacy in patients with HFpEF.</p></div>","PeriodicalId":14687,"journal":{"name":"JACC. Heart failure","volume":"12 9","pages":"Pages 1509-1527"},"PeriodicalIF":10.3,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141874824","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}